Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study. [artículo]
Por: Pulido Ortega, Federico [Unidad VIH]
| Rubio García, Rafael [Unidad de VIH].
Colaborador(es): Servicio de Medicina Interna.
Editor: HIV medicine, 2013 Tipo de medio: JOUR Recursos en línea: Solicitar documento Resumen: OBJECTIVES: Lipoatrophy is a long-term adverse effect of some antiretrovirals that affects quality of life, compromises adherence and may limit the clinical impact of HIV treatments. This paper explores the effect of tenofovir/emtricitabine (TDF/FTC) on the amount of limb fat in patients with virological suppression.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC837 (Navegar estantería) | Disponible |
Contiene 33 referencias
OBJECTIVES: Lipoatrophy is a long-term adverse effect of some antiretrovirals that affects quality of life, compromises adherence and may limit the clinical impact of HIV treatments. This paper explores the effect of tenofovir/emtricitabine (TDF/FTC) on the amount of limb fat in patients with virological suppression.
No hay comentarios para este ejemplar.